What question did this study set out to answer?

This research aims to evaluate the effectiveness of niraparib rechallenge combined with bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.

April 25, 2026

Returning to PARP inhibition: Rechallenge with Bevacizumab in Ovarian Cancer

Key Points

This research aims to evaluate the effectiveness of niraparib rechallenge combined with bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.
Randomized trial evaluated n=XX patients with platinum-sensitive recurrent ovarian cancer previously treated with PARPi.
Patients received niraparib in combination with bevacizumab as maintenance therapy.
Primary endpoint assessed was progression-free survival (PFS) after 6 months.
Achieved a 68% progression-free survival (PFS) rate at 6 months.
Indicated potential to overcome acquired resistance to PARP inhibitors, especially in patients with favorable platinum sensitivity.

Abstract

The KGOG 3056/NIRVANA-R trial demonstrated that niraparib rechallenge combined with bevacizumab may potentially be a promising maintenance strategy in patients with platinum-sensitive recurrent ovarian cancer (PSROC) previously treated with PARPi. With a 68% 6-month progression-free survival (PFS) rate, this combination may synergistically be able to overcome acquired PARPi resistance, particularly in patients with favorable platinum sensitivity.

Bookmark

Cite This Study

Sachdeva et al. (Thu,) studied this question.

synapsesocial.com/papers/69ec5a6b88ba6daa22dabfc0 https://doi.org/https://doi.org/10.1158/1078-0432.ccr-26-0534

Bookmark